Celgene Global Health visceral leishmaniasis series 1
Select a pre‑clinical candidate from the CGH VL series for the treatment of visceral leishmaniasis
last phase of drug development




updated 28 Feb 2019
A novel series of heterocyclic compounds for visceral leishmaniasis was optimized by Celgene in collaboration with London School of Hygiene & Tropical Medicine and Advinus, and with advice from DNDi. In 2016, an in vivo proof-of-concept was achieved for this series.
In 2018, because of poor pharmacokinetics and a lack of safety margins following extensive exploration, the decision was made to stop this series. A new screen has begun with a new sub-set of the Celgene library of compounds with the goal to identify novel lead series.
- Germany - Federal Ministry of Education and Research (BMBF) through KfW
- The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
- UK - UK International Development
- Médecins Sans Frontières International
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.